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Abstract: Nitric oxide (NO), generated by phago-
cytes at inflammation sites, contributes to regulate
immune responses through autocrine and para-
crine actions on bystander cells. Among the latter
are dendritic cells (DCs). Little is known about
regulation of DC function by NO, especially in the
human system. We exposed human monocyte-de-
rived DCs to the NO donor (z)-1-[2-(2-amino-
ethyl)-N-(2-ammonioethyl)amino] diazen-1-ium-
1,2 diolate (DETA-NO) during their maturation
process induced by treatment with tumor necrosis
factor  or lipopolysaccharide or by CD40 activa-
tion. We report here that after exposure to DETA-
NO, DCs exhibit a significantly increased ability to
activate T lymphocytes stimulated by mycobacte-
rial antigens, Staphylococcus aureus Cowen strain
B, allo-antigens, or cross-linking of the CD3–T cell
receptor complex. This effect persists after re-
moval of DETA-NO, depends on the generation of
cyclic guanosine 5-monophosphate, and is a result
of enhanced release by DCs of soluble factors, in
particular interleukin (IL)-12. This modulation of
DC function is a result of a synergism between NO
and the various maturation stimuli, as neither en-
hanced T cell activation nor IL-12 release was
observed after DC exposure to DETA-NO only.
These results provide the first evidence that NO
acts as a cosignaling molecule regulating human
DC response to maturation stimuli. J. Leukoc.
Biol. 73: 253–262; 2003.
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INTRODUCTION
Nitric oxide (NO) has been recognized as one of the most
versatile players in the immune system [1]. This short-lived
messenger is generated during immune responses, mainly
through the inducible isoform of the NO synthase (iNOS),
expressed in phagocytes after their activation by cytokines and
bacterial products [2]. Because of its diffusible nature, NO acts
in an autocrine and paracrine manerr on neighboring cells
[3]. NO endows activated macrophages and microglial cells
with antimicrobial and cytotoxic activity, enhances the func-
tion of T and natural killer cells, and regulates the generation
of cytokines and chemokines at the site of infection [3–9].
Targeted deletion of iNOS renders mice more susceptible to
infections [10].
Increasing evidence indicates that NO also modulates the
function of dendritic cells (DCs), which are professional, anti-
gen-presenting cells involved in the initiation and in the main-
tenance of immune responses. Immature DCs capture antigens
at the site of inflammation and process and present them to T
lymphocytes in secondary lymphoid organs [11]. These events
are accompanied by DC maturation and are orchestrated by
proinflammatory signals generated at the site of infection [11].
Experiments in rodents show that DCs can express iNOS and
that this expression results in a reduced antigen-presenting
function [12, 13]. In addition, generation of NO by iNOS-
expressing DCs contributes to the clonal deletion of thymocytes
and to the suppression of autoreactive T cells during experi-
mental, allergic encephalomyelitis [14–16].
The role of NO in regulating human DC function is less
clear. In liver diseases characterized by chronic inflammation
of peripheral tissues, namely hepatocellular carcinoma and
primary biliary cirrhosis, DCs have been found to express
iNOS, and this correlates with their reduced antigen-present-
ing function [17, 18]. DCs from healthy donors, however, do not
express iNOS when immature nor after exposure to lipopoly-
saccharides (LPS) and cytokines [18, 19]. Nevertheless, at the
inflammation site, these DCs are exposed to NO diffusing from
other NO-generating, immune cell types, together with proin-
flammatory molecules [4]. Recent studies in various cell types
have shown that this paracrinely generated NO regulates spe-
cifically and selectively the signal transduction pathways ac-
tivated by one such proinflammatory molecule, tumor necrosis
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factor  (TNF-) [19–21]. This opens the possibility that
paracrinely generated NO regulates maturation of human DCs
induced by TNF- and possibly other maturation signals, thus
contributing to the antigen-presenting function of these cells
during immune responses. So far, however, such a possibility
has not been investigated.
To address this question, we studied the exposure of human
DCs to NO during the TNF--induced maturation process [19,
22]. To this end, we used the NO donor (z)-1-[2-(2-aminoethyl)-
N-(2-ammonioethyl)amino] diazen-1-ium-1,2 diolate (DETA-
NO), which releases NO constantly and at defined concentra-
tions [23]. In our model, DETA-NO was added only during the
DC maturation process and was subsequently removed. Our
results show that exposure of maturing DCs to NO increases
their ability to activate T lymphocytes. This effect of NO is
persistent and independent of antigen uptake and processing.
In addition, it requires activation of guanylate cyclase and
generation of cyclic guanosine 5-monophosphate, (cGMP) and
is mediated through the release by DCs of interleukin (IL)-12.
Similar cGMP-dependent, enhancing effects of NO on T cell
activation and IL-12 release were also observed when DC
maturation was obtained by treatment with LPS or by CD40
cross-linking. These results suggest that NO exerts a general,
regulatory function during human DC maturation.
MATERIALS AND METHODS
Reagents
The following reagents were purchased as indicated: fluorescein isothiocyanate
(FITC)-labeled mouse monoclonal antibodies (mAb) anti-human CD1a, CD40,
CD80, CD83, CD86, and major histocompatibility complex (MHC) class I and
class II from Caltag (Burlingame, CA); mAb anti-human CD28 from Becton
Dickinson (San Jose´, CA); recombinant human (rh)TNF-, DETA-NO, and
H-[1,2,4] oxadiazolo [4,3-]quinoxalin-1-one (ODQ) from Alexis Italia (Flo-
rence); rhIL-4, IL-12, and granulocyte macrophage-colony stimulating factor
(GM-CSF) from Strathmann Biotech GMBH (Hannover, Germany), Genzyme
(Milano, Italy), and Mielogen-Schering Plough (Milano, Italy), respectively;
Fycoll-Paque from BioChrom (Berlin, Germany); methyl-3H thymidine from
Amersham Pharmacia Biotech (Little Chalfont, Buckinghamshire, UK); Myco-
bacterium tuberculosis-derived tuberculin-purified protein derivative (PPD)
from Statens Serum Institut (Copenhagen, Denmark); magnetic Dynabeads
M-450 goat anti-mouse immunoglobulin G (IgG) from Dynal (Oslo, Norway);
the anti-human IL-12 neutralizing mAb (clones 17F7 and 20C2, mouse IgG1);
and the isotype-control mAb, kindly provided by Lars Rogge (Roche Milano
Ricerche, Milan, Italy). The anti-CD40 mAb, purified from the 626.1 hybrid-
oma, was kindly provided by Donata Vercelli (University of Arizona, Tucson,
AZ). The mAb anti-human CD3 was purified from the hybridoma (OKT3)
obtained from American Type Culture Collection (Manassas, VA). The re-
agents for tissue culture were from Gibco (Basel, Switzerland), except for fetal
calf serum (FCS; clone III), obtained from Hyclone-Celbio (Milan, Italy); 8
Br-cGMP, Staphylococcus aureus Cowen strain B (SEB), and all of the other
reagents were from Sigma Chemical Co. (Milan, Italy).
The conditions of use of DETA-NO, 8 Br-cGMP, and ODQ were selected on
the basis of previous experiments in human DCs and in cell lines derived from
monocytes and macrophages [19, 23, 24]. In particular, at the concentrations
used in this study, these compounds appear not to be toxic and are still able
to trigger biological effects [19, 23, 24].
All solutions were prepared endotoxin-free. Endotoxin contamination in all
drug solutions was routinely assessed by the Lymulus amoebocyte gelification
test, performed according to the manufacturer’s instructions (PBI, Milan, Italy)
before administration to DCs. All reagents, including the medium, scored
negative.
Preparation and characterization of DCs
and lymphocytes
Peripheral blood mononuclear cells (PBMC) from healthy blood donors were
obtained from buffy coats (kindly provided by the Blood Transfusion Depart-
ment of The DIBIT-H San Raffaele Institute, Milan, Italy) or heparinized blood
drawn by venipuncture. Standard gradient separation procedures on Fycoll-
Paque were used [19]. PBMC were resuspended in RPMI 1640 containing 10%
FCS, 2 mM glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin, from
hereon referred to as “complete medium,” and were allowed to adhere on
six-well plates (Costar, Cambridge, MA) for 1 h at 37°C. Nonadherent cells
were discarded. To derive immature DCs, PBMC were then cultured for 7 days
in complete medium in the presence of human GM-CSF (50 ng/ml) and IL-4
(1000 U/ml) [19]. Depletion of residual T lymphocytes from immature DCs was
routinely performed by incubating the cell preparations with the anti-CD3 mAb
(1 g/106 cells) and goat anti-mouse IgG-coated Dynabeads M-450. Anti-CD3
mAb-bound T cells were removed with a magnet according to the manufac-
turer’s instructions. Purified DC preparations were routinely checked for
contaminating lymphocytes by flow cytometry using FACScan Plus (Becton
Dickinson, Sunnyvale, CA). Residual lymphocytes accounted for less than 1%
of total cells (not shown). DCs were then incubated for 48 h with (mature DCs)
or without (immature DCs) human TNF- (50 ng/ml), LPS (1 g/ml), or an
anti-CD40-activating mAb (10 g/ml) in the presence or absence of DETA-NO
(50 M), 8-Br-cGMP (3 mM), or ODQ in various combinations, as specified in
Results below. Before the coculture with lymphocytes, DCs were washed twice
in complete medium to remove all the various compounds and were then
irradiated (2500 rad). Removal of the NO donor was routinely checked by
verifying absence of NO generation in washed DC suspensions using a NO
electrode (World Precision Instruments, Sarasota, FL) [23]. To assess DC
phenotype, cells (5105) were incubated for 30 min at 4°C in phosphate-
buffered saline (PBS) containing 1% FCS with FITC-conjugated mAb specific
to MHC class I and class II, CD1a, CD40, CD80, CD83, or CD86. Expression
of the various molecules was evaluated by flow cytometry [19]. Data were
analyzed with Cell Quest software (Becton Dickinson, Sunnyvale, CA). DC
viability after the various treatments was assessed by propidium iodide/
Annexin-V staining, exactly as described [19].
T cell-enriched preparations were obtained as follows: PBMC (5106),
obtained from PPD-positive or -negative donors, were washed in RPMI-1640
medium and incubated in complete medium containing 0.5% carbonyl iron for
60 min at 37°C on a rotating wheel. Phagocytic cells were removed with a
magnet as described [25]. With these procedures, residual monocytes ac-
counted for less than 1% of the cell preparations, as checked with anti-CD14
mAb by flow cytometry (not shown).
Measurement of cGMP generation
Immature DCs (1106 cells/sample) were incubated for 15 min at 37°C in PBS
with the phosphodiesterase inhibitor 3-isobutyl-1-methyl xanthine (0.5 mM)
and were then exposed for an additional 30 min to increasing concentrations
of ODQ (0–5 M) in the presence or absence of DETA-NO (50 M). The
reaction was terminated by addition of ice-cold trichloroacetic acid (final
concentration: 7.5%). After ether extraction, cGMP levels were measured using
a radioimmunoassay kit and were normalized on cellular proteins, determined
by the bicinchoninic acid assay procedure (Pierce, Rockford, IL).
Lymphocyte proliferation assays
For mixed lymphocyte reactions (MLRs), DCs, pretreated as described above,
were cocultured at different ratios on 96-well flat-bottom plates together with
heterologous lymphocytes, which were added at the constant concentration of
105 cells/well. DC-to-lymphocyte ratios ranged from 1:1000 to 1:5. For anti-
gen-driven proliferation assays, DCs (2104 cells/well) were incubated with
autologous lymphocytes (105 cells/well) in the presence of 1 g/ml PPD, 0.2
g/ml SEB, or 0.1 g/106 cells anti-CD3 mAb. In some experiments, lym-
phocytes were stimulated with SEB (0.2 g/ml) on plates precoated by a 3-h
incubation (37°C) with anti-CD28 mAb (5 g/ml) or on plates precoated with
the anti-CD28 mAb and anti-CD3 mAb (1 g/ml) in the presence of a
DC-conditioned culture medium (1:1). This DC-conditioned medium was
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freshly prepared the day of the experiment by collecting supernatants condi-
tioned for 48 h by the various DC preparations described above. The super-
natant was filtered through a 0.2 m Millipore filter before use. T cell
proliferation was evaluated by measuring incorporation of methyl-3H thymi-
dine (0.8 Ci/well), which was added to the cocultures during the last 6 h. To
this end, cells were harvested, and radioactivity was measured using a Wallac
LKB -counter.
Cytokine assays
T cells were cocultured with DCs (105 T cells plus 2104 DCs) and were
pretreated as described above on 96-well plates in 200 l medium. IL-2, IL-4,
and interferon- (IFN-) concentrations were determined in the medium 48 h
after stimulation using commercially available enzyme-linked immunosorbent
assay (ELISA) kits specific for each cytokine (R&D Systems, Space Import
Export, Milan, Italy). IL-12p70 was measured in supernatants conditioned for
48 h by DCs pretreated with or without TNF-, LPS (1 g/ml), or the
anti-CD40 mAb (10 g/ml) in the presence or absence of DETA-NO using the
Quantikine High-Sensitivity kit (detection limit: 0.5 pg/ml), following the
manufacturer’s instructions (R&D Systems).
Statistical analysis
The results are expressed as means  SEM; n represents the number of
individual experiments. Statistical analysis was performed using the Student’s
t-test for unpaired variables (two-tailed). In the figures, ** and *** refer to
statistical probabilities (P) of 0.01 and 0.001, respectively, measured in
the various experimental conditions as detailed in the legends to figures.
RESULTS
NO enhances T lymphocyte activation by
TNF--treated DCs
Immature DCs were treated for 2 days with or without TNF-
(50 ng/ml) in presence or absence of the NO donor DETA-NO
(50 M) and were then washed free of the cytokine and the NO
donor. At the concentration used, this NO donor releases a
constant flux of 50  2.3 nM NO (n	4), as measured by a NO
electrode [23] and does not affect DC viability (see also ref.
[19]). Thus, antigen-presenting function of pretreated DCs was
evaluated by measuring DC-induced proliferation of allogeneic
T lymphocytes in MLRs (Fig. 1A) or autologous T lymphocytes
stimulated with SEB (0.2 g/ml), PPD (1 g/ml), or anti-CD3
mAb (0.1 g/106 cells; Fig. 1B). In all these experimental
settings, the pretreatment with DETA-NO alone resulted in no
changes in DC-induced T cell proliferation. By contrast, when
administered to DCs together with TNF-, the NO donor
increased DC ability to stimulate T cells. T cell proliferation
was significantly higher than that induced by untreated DCs or
DCs pretreated with TNF- alone, in MLRs (Fig. 1A), and in
autologous reactions in the presence of SEB, anti-CD3 mAb, or
Fig. 1. NO enhances the ability of TNF--treated
DCs to induce T cell activation. Immature DCs were
treated for 2 days with or without TNF- (50 ng/ml)
in the presence or absence of DETA-NO (50 M).
(A) These pretreated DCs were cocultured at the
indicated ratios with a fixed number of allogeneic T
cells (105 cells/well); proliferation (3H-thymidine
incorporation in T cells) was measured after 3 and
5 days of DC/T cell coculture. (B) Pretreated DCs
(2104) were cocultured with 105 autologous T
cells in the presence of SEB (0.2 g/ml), anti-CD3
(0.1 g/106 cells), and PPD (1 g/ml) or without
any stimulus. Proliferation was measured after 3
days. (C) IFN- and IL-2 secretion were measured
in the supernatant from 3 days coculture of 105
autologous T cells with or without 2  104 pre-
treated DCs and in the presence or absence of SEB.
Asterisks indicate statistical significance, measured
as indicated in Materials and Methods, of TNF-/
DETA-NO DCs versus TNF--treated DCs (n	8).
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PPD (Fig. 1B). Regardless of the pretreatment, DCs alone
induced no significant proliferation of unstimulated, autologous
T cells (Fig. 1, A and B).
The concentration of IFN-, IL-2, and IL-4 in the medium
under the various experimental conditions described above was
assessed. Figure 1C shows the values measured for IFN- and
IL-2 using SEB-stimulated T cells. Concentrations of IFN-
and IL-2 detected in the presence of DCs pretreated with
DETA-NO alone were similar to those observed with immature,
untreated DCs. Pretreatment of DCs with TNF- resulted in
increased release of cytokines, which was further, significantly
enhanced in the presence of the NO donor. By contrast, release
of IL-4 was not modified by DC pretreatment with DETA-NO.
(Using SEB-stimulated T cells, values were 3.20.11 and
3.40.19 pg/ml with untreated DCs and DCs pretreated with
TNF-, respectively, and 2.90.12 and 3.10.09 pg/ml with
DCs pretreated with DETA-NO and DETA-NO plus TNF-,
respectively; n	3). In the absence of SEB, no significant
release of IFN-, IL-2, and IL-4 was observed, regardless of
whether lymphocytes were cultured alone or in the presence of
untreated, immature DCs.
The effect of NO on T lymphocyte activation by
TNF--treated DCs is dependent on the
generation of cGMP
NO biological effects are mediated through signaling pathways,
dependent and independent of their ability to activate guany-
late cyclase and generate cGMP [2]. Recently, we have shown
that NO triggers cGMP generation in immature human DCs and
that the cyclic nucleotide contributes to regulate endocytosis in
these cells [19]. In the present experimental setting, adminis-
tration of DETA-NO resulted in generation of cGMP, which
was inhibited in a concentration-dependent way by ODQ, a
specific guanylate-cyclase inhibitor [26] (Fig. 2). Therefore,
we investigated whether the NO-dependent enhancement of
DCs antigen-presenting ability was mediated through cGMP.
To this end, immature DCs were pretreated with or without
TNF- in the presence or absence of the membrane-permeant
cGMP analog 8 Br-cGMP (3 mM), of DETA-NO, or of DETA-
NO, together with increasing concentrations of ODQ (0–5 M).
DCs treated with 8 Br-cGMP and TNF- induced proliferation
of T cells and secretion of IFN- and IL-2 higher than those
induced by TNF--treated DCs and with a pattern similar to
that observed with DCs treated with DETA-NO and TNF-
(Fig. 3, A–C, left). Pretreatment with ODQ, although ineffec-
tive in DCs treated with TNF- only, reversed in a concentra-
tion-dependent way the effect induced by coadministration of
TNF- and DETA-NO on the proliferation of T cells and the
secretion of cytokines (Fig. 3, A–C, right).
A soluble factor released by DCs treated with
TNF- and NO is responsible for the enhanced
T lymphocyte activation
TNF--induced differentiation of DCs toward a mature, anti-
gen-presenting phenotype involves the coordinated up-regula-
tion of proteins on the plasma membrane, including MHC
classes I and II and costimulatory molecules, as well as the
release of soluble factors [27].
We examined whether NO modulates plasma membrane ex-
pression of MHC classes I and II, CD1a, CD83, and costimulatory
CD40, CD80, and CD86 molecules. The pattern of expression of
these molecules in immature and TNF--treated DCs is shown in
Figure 4. Treatment of immature DCs for 48 h with DETA-NO
did not change expression of MHC classes I and II nor any of the
costimulatory molecules investigated. Likewise, the NO donor did
not modify the pattern of expression of these molecules elicited by
a 48-h maturation with TNF- (Fig. 4).
Whether release of soluble factors accounted for the effects
of NO-treated DCs on T cell proliferation was next investi-
gated. Immature DCs were treated for 2 days with or without
TNF- in the presence or absence of DETA-NO, were washed
free of the cytokine and the NO donor, and were maintained for
a further 2 days in culture. Culture medium was then removed
and assayed for its ability to modulate proliferation of T lym-
phocytes in an activation system consisting of a CD28-activat-
ing mAb administered together with SEB or anti-CD3 mAb.
Both of these activation systems triggered significant T cell
proliferation (Fig. 5A). Addition of the supernatant from cul-
tures of untreated DCs or DCs treated with only DETA-NO did
not modify this activation. By contrast, the supernatant from
TNF--treated DCs increased T cell proliferation (more evi-
dently in the anti-CD28/SEB model). In both of the activation
systems analyzed, this effect was significantly greater using
supernatants from DCs coincubated with TNF- and
DETA-NO (Fig. 5A).
Fig. 2. Generation of cGMP by DCs. Immature DCs were pretreated for 15
min with the phosphodiesterase inhibitor 3-isobutyl-1-methyl xanthine (0.5
mM) and were then incubated for 30 min with increasing concentrations of
ODQ (0–5 M) in the presence or absence of DETA-NO (50 M). cGMP
generation in the various experimental conditions was measured using a
radioimmunoassay specific for the cyclic nucleotide.
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Increased release of IL-12 is responsible for the
enhanced T cell activation by NO/TNF-
-treated DCs
Among the proinflammatory cytokine released by DCs, IL-12
has been shown to play pivotal roles in T cell activation [28].
We thus evaluated whether NO regulates release of IL-12. As
shown in Figure 5B, release of IL-12 was slightly increased by
pretreatment of DCs with TNF- and was further, significantly
enhanced when DETA-NO or 8 Br-cGMP was coadministered
with TNF-. The dependence on cGMP generation of the effect
of DETA-NO was further confirmed by the observation that
administration of ODQ (3 M) together with DETA-NO and
TNF- gave rise to IL-12 generation similar to that observed in
DCs pretreated with TNF- alone. Basal IL-12 release was not
modified by DC pretreatment with DETA-NO, 8 Br-cGMP, or
ODQ alone. To evaluate whether this increased secretion of
IL-12 was involved in stimulation of T lymphocyte proliferation
by DCs, we tested the effect of a neutralizing anti-IL-12 Ab
cocktail [29]. Inhibition of IL-12 did not significantly modify T
cell proliferation induced by the supernatant from untreated
and TNF--pretreated DCs. This applied to anti-CD28/SEB
and anti-CD28/anti-CD3-stimulated T cells (Fig. 5C). In con-
trast, the neutralizing anti-IL-12 Ab cocktail abolished the
enhancing effect on T cell proliferation induced by DETA-NO
when combined with TNF-, giving rise to proliferation values
similar to those observed with TNF- alone. These effects
appeared to be specific, as they were not observed in the
presence of an isotype-control Ab.
NO enhances T lymphocyte activation by DCs
matured with LPS or an anti-CD40 mAb through
cGMP-dependent IL-12 release
To assess whether the effect of NO and the mechanism of its
action were specific for TNF--induced DC maturation or a
more general phenomenon, we investigated DC maturation
induced by LPS and activation of CD40. Immature DCs were
Fig. 3. The NO-dependent enhancement of the
ability of DCs to induce T cells activation is medi-
ated through cGMP. Immature DCs were incubated
for 2 days with or without TNF- (50 ng/ml) in the
presence or absence of DETA-NO (50 M), the
membrane-permeant cGMP analog 8 Br-cGMP (3
mM), or the inhibitor of soluble guanylate cyclase
ODQ (0–5 M), as indicated in the keys to the
various panels. Autologous T cells (105) were then
cocultured with or without 2 x 104 pretreated DCs
in the presence or absence of SEB (0.2 g/ml). T
cell activation was evaluated as proliferation (A)
and secretion of IFN- and IL-2 (B and C) after 3
days. Asterisks indicate statistical significance,
measured as indicated in Materials and Methods
(n	8).
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treated for 2 days with or without LPS (1 g/ml) or an anti-
CD40-activating mAb (10 g/ml) in the presence or absence of
DETA-NO, 8 Br-cGMP, and ODQ (3 M) in various combi-
nations. The cells were then washed free of all the treatments.
LPS treatment and CD40 cross-linking triggered DC matura-
tion, as assessed by increased expression of CD80, CD83,
CD86, and MHC class II, none of which was modified by
cotreatment with DETA-NO (Table 1). When administered to
DCs, together with LPS or the anti-CD40 mAb, however, the
NO donor increased DC ability to stimulate T cells in MLRs
(Fig. 6, A and B) and in autologous reactions in the presence
of SEB (Fig. 6, C and D). As these effects of NO were similar
to those observed with TNF--treated DCs, we evaluated
whether they were a result of IL-12 release. As already re-
ported [30], treatment of DCs with LPS or anti-CD40 Ab
resulted in the release of concentrations of IL-12 higher than
those observed after DC treatment with TNF-. These values
were further, significantly increased by the coincubation of
DCs with DETA-NO (Fig. 7, A and B).
We then investigated the effects on T cell proliferation in the
anti-CD28/SEB system of supernatants obtained from 2 days of
culture of DCs with LPS or anti-CD40 mAb, prepared as
described above for the experiments with TNF-. Both condi-
tions gave rise to T cell proliferation, which was significantly
increased when supernatants were obtained from DCs also
incubated with DETA-NO (Fig. 7, C and D). Administration of
the neutralizing anti-IL-12 Ab cocktail reduced T cell prolif-
eration induced by the supernatant from LPS and anti-CD40-
pretreated DCs and abolished the enhancing effect on T cell
proliferation induced by DETA-NO.
Similar to the experiments with TNF-, also in the experi-
ments with LPS- and anti-CD40-treated DCs, we found that all
the effects of NO were dependent on cGMP generation, as they
were mimicked by 8 Br-cGMP and reversed by ODQ (Figs. 6,
C and D, and 7, A and B).
To further evaluate the role of released IL-12, we measured
the effect of adding increasing concentrations of exogenous
IL-12 to T lymphocytes in the anti-CD28/SEB experimental
system. As shown in Figure 7E, IL-12 increased T cell prolif-
eration in a concentration-dependent manner. The effect of
exogenous IL-12 appeared in the range of that induced by
supernatants containing comparable concentrations of endog-
enously generated IL-12 (cf. Fig. 7E with C and D and with
Fig. 5C).
DISCUSSION
In inflamed peripheral tissues, DCs are exposed simulta-
neously to a variety of signals, among which is NO [1, 4]. A role
for NO in regulating DC functions had already been proposed,
however, based mostly on results obtained in the murine sys-
tem [1, 4]. The latter is different from the human system. In
fact, at variance with their murine counterparts, DCs from
healthy donors are unable to express iNOS [19]. Thus, they are
exposed, not to autocrine but only to paracrine NO, i.e., the one
generated at the site of inflammation by neighboring, NOS-
competent cells.
Our experimental protocol was designed to expose DCs to
NO only during their maturation, which was triggered with
three different stimuli, TNF-, LPS, and an activating, anti-
CD40 mAb. This approach allowed us not only to mimick the
effects of an exposure of human DC to paracrine NO but also
to dissect those effects of NO that are accounted for by a direct
action on DCs. Under these conditions, we found that NO,
although ineffective when administered alone, synergizes with
each of the three tested stimuli to trigger a modified DC
maturation program, resulting in an enhanced ability to stimule
T lymphocyte proliferation. This effect of NO was found to
possess three main characteristics. The first is that it is inde-
Fig. 4. Phenotypic characterization of DCs induced to mature with TNF- in the presence or absence of NO. Immature DCs were treated for 2 days with or without
TNF- (50 ng/ml) in the presence or absence of DETA-NO (50 M). Cell preparations were analyzed by flow cytometry after staining with FITC-conjugated Ab
specific for the surface antigens specified at the top of each column (solid-line histograms). Cell autofluorescence is indicated by the superimposed, thin-line
histograms. The results shown are from 1 experiment representative of 10 consistent ones. UT, Untreated.
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pendent of antigen uptake/processing, as it was observed in
MLRs; in autologous reactions in the presence of SEB, anti-
CD3 mAb, or PPD; and in the presence of the DC-conditioned
medium only. Second, the enhanced DC ability of stimulating
T lymphocyte proliferation persists after removal of NO, sug-
gesting that priming with NO in peripheral tissues may be
sufficient to exert a licensing effect on antigen presentation in
lymphoid organs. Finally, the effect of NO appears indepen-
dent of the stimulus that triggers DC maturation, as it was
equally observed with LPS, TNF-, or the anti-CD40 mAb.
This, together with the observation that the increased ability to
activate T cells by NO was only observed when NO and each
of the above stimuli were coadministered to DCs, indicate that
NO acts through regulation of specific, transductional events
activated by these maturation stimuli. Paracrine NO, therefore,
appears to function as a cosignal influencing the cross-talk
between DCs and T cells.
We investigated the possible mechanisms through which NO
exerts its action on maturing DCs and found it to depend in all
cases on activation of guanylate cyclase and generation of
cGMP, as demonstrated by experiments with the membrane-
permeant cGMP analog 8-Br-cGMP and the guanylate-cyclase
inhibitor ODQ. Although DC exposure to NO did not modify
the maturation-regulated expression of MHCs and major co-
stimulatory molecules, it greatly affected release to the extra-
cellular milieu. In particular, with all three maturation stimuli
tested, we identified increased release of IL-12 as relevant to
the cGMP-dependent effect of NO. The role of IL-12 was
investigated by two experimental approaches. First, we added
an IL-12 neutralizing Ab to the supernatants from the various
DC cultures. Under these conditions, the enhancing effect of
NO on T cell proliferation disappeared. Second, we studied the
effect of exogenous IL-12 added to T lymphocytes in the
anti-CD28/SEB system and found T cell proliferation stimu-
lated in a concentration-dependent way, as already reported in
a similar system [31]. This effect was in the range of that
induced by supernatants containing comparable concentra-
tions of IL-12 produced by DCs exposed to NO, together
with LPS, TNF-, or the anti-CD40 mAb. From these ex-
periments, we conclude that increased release of IL-12
explains the observed effect of NO/cGMP-treated DCs on T
lymphocyte proliferation.
Activation of guanylate cyclase and generation of cGMP
mediate many effects of NO in a variety of cells, including
signaling events activated by TNF- and LPS (see, e.g., refs.
[20, 21, 32–34]). Despite the relevant role played by NO/cGMP
Fig. 5. Release of IL-12 is crucial to enhanced T lymphocyte activation by
DCs treated with TNF- and NO. Supernatants were collected from DCs
pretreated for 2 days with or without TNF- (50 ng/ml) in the presence or
absence of DETA-NO (50 M), 8 Br-cGMP (3 mM), or ODQ (3 M). (A) T cell
proliferation in the presence or absence of the various supernatants, as
indicated on the left, was stimulated for 3 days with anti-CD3 (1 g/ml)/anti-
CD28 (5 g/ml) mAb or SEB (0.2 g/ml)/anti-CD28 mAb, as detailed in
Materials and Methods. Control experiments with unstimulated T cells were
run in parallel. (B) Concentration of IL-12p70 in the supernatants, evaluated
by ELISA. (C) Experiments were performed as in A but in the absence (nil) or
presence (IL-12) of an IL-12 neutralizing mAb cocktail, as described in
Materials and Methods. Experiments with an isotype-control Ab were per-
formed in parallel. Asterisks indicate statistical significance, measured as
indicated in Materials and Materials; s.n., Statistically not significant (n	6).
TABLE 1. Phenotypic Characterization of DC Maturation Induced by LPS or by CD40 Cross-linking in the Presence or Absence of NO
CD80 CD83 CD86 MHC class II
Untreated DCs 1.70  0.08 1.02  0.06 14.9  0.82 11.5  0.32
LPS DCs 3.21  0.25 2.10  0.16 28.2  1.12 21.5  1.24
LPS/DETA-NO DCs 3.31  0.27 2.06  0.13 28.4  0.92 21.6  1.45
CD40 DCs 7.80  0.32 8.31  0.29 54.8  2.12 27.9  1.33
CD40/DETA-NO DCs 7.84  0.24 8.40  0.42 55.1  2.66 28.1  1.42
Immature DCs were treated for 2 days with or without LPS (1 g/ml) or an anti-CD40 mAb (10 g/ml) in the presence or absence of DETA-NO (50 M). Cell
preparations were analyzed by flow cytometry after staining with FITC-conjugated Ab specific for CD80, CD83, CD86, and MHC class II. Values shown are the
relative fluorescence intensities  SEM measured for each FITC-conjugated Ab versus cell autofluorescence (n	6).
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in immune responses, however, evidence about cGMP regulat-
ing maturation signal-transduction pathways in DCs is still
limited to a recent report by our group, showing a cGMP-
dependent reduction by NO of the levels of ceramide observed
after DC treatment with TNF- [19]. The identification in three
distinct signal-transduction pathways of IL-12 as the mediator
of the NO/cGMP action may provide a first clue toward eluci-
dating the molecular events regulated by the cyclic nucleotide
during DC maturation.
Generation of IL-12 by DCs is a tightly regulated event [28].
Production of this cytokine can be elicited by most pathogens
and increased further by activated CD40 ligand-positive T
cells [35]. DC maturation, however, does not necessarily com-
prise IL-12 secretion. For example, DCs matured in the pres-
ence of cholera toxin or CD95 ligand fail to secrete IL-12 [36].
Similarly, proinflammatory cytokines, such as IL-1 and
TNF-, appear poor activators of IL-12 secretion [37]. Our
results provide evidence that the TNF--induced phenotype is
reversed in the presence of NO.
Sustained generation of NO as a consequence of iNOS
up-regulation in competent immune cells is among the effects
of LPS, TNF-, and CD40 ligand [1]. NO, therefore, appears to
be part of a feed-forward loop aimed at amplifying immune
responses through an increased antigen-presenting function of
DCs. Of importance, we found that NO increases secretion by
T cells of IFN- and IL-2 but not of IL-4. This novel function
of NO might, therefore, contribute to explain the mechanisms
by which cooperation among IL-12, NO, and other T helper cell
Fig. 6. NO enhances the ability of LPS- and anti-CD40 mAb-treated DCs to induce T cell activation. Immature DCs were treated for 2 days with or without LPS
(1 g/ml, A and C) or an anti-CD40 mAb (10 g/ml, B and D) in the presence or absence of DETA-NO (50 M), 8 Br-cGMP (3 mM), or ODQ (3 M). (A and
B) These pretreated DCs were cocultured at the indicated ratios with a fixed number of allogeneic T cells (105 cells/well); proliferation (3H-thymidine incorporation
in T cells) was measured after 5 days of DC/T cell coculture. (C and D) Pretreated DCs (2x104) were cocultured with 105 autologous T cells in the presence of
SEB (0.2 g/ml) or without any stimulus. Proliferation was measured after 3 days. Asterisks indicate statistical significance, measured as indicated in Materials
and Methods (n	6).
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type 1 cytokines contributes to healing infections in vivo
[38–41].
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